Reported 1,095,740 shares, up 15,452 (1.4%) from the prior quarter.
Reported value 261.3%; share count 1.4% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 765000 |
| 2022-03-31 | 718000 |
| 2022-06-30 | 714000 |
| 2022-09-30 | 608000 |
| 2022-12-31 | 0 |
| 2025-09-30 | 1117604 |
| 2025-12-31 | 2824305 |
| 2026-03-31 | 3767058 |
| 2026-06-30 | 4493998 |
| 2026-09-30 | 16238867 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Added | 1,095,740 | +15,452 (1.4%) | 1.89% | $16,238,867 | 2026-10-09 | |
| Q2 2026 | Added | 1,080,288 | +7,052 (0.7%) | 0.55% | $4,493,998 | 2026-07-07 | |
| Q1 2026 | Added | 1,073,236 | +38,692 (3.7%) | 0.53% | $3,767,058 | 2026-04-08 | |
| Q4 2025 | Added | 1,034,544 | +519,519 (100.9%) | 0.39% | $2,824,305 | 2026-01-14 | |
| Q3 2025 | New | 515,025 | +515,025 (0.0%) | 0.16% | $1,117,604 | 2025-10-07 | |
| Q4 2022 | Reduced | 0 | -63,479 (-100.0%) | 0 | $0 | 2023-02-10 | |
| Q3 2022 | Reduced | 63,479 | -1,211 (-1.9%) | 0.15% | $608,000 | 2022-11-14 | |
| Q2 2022 | Added | 64,690 | +21,585 (50.1%) | 0.17% | $714,000 | 2022-08-05 | |
| Q1 2022 | Added | 43,105 | +3,039 (7.6%) | 0.15% | $718,000 | 2022-05-06 | |
| Q4 2021 | Added | 40,066 | +14,772 (58.4%) | 0.16% | $765,000 | 2022-02-02 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
368 managers reported IOVANCE BIOTHERAPEUTICS INC for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| BlackRock Inc | Added | 37,903,960 | +946,279 | < 0.01% | $561,736,688 | 9 qtrs |
| MHR FUND MANAGEMENT LLC | Unchanged | 28,967,103 | 0 | 21.06% | $429,292,466 | 16 qtrs |
| STATE STREET CORPORATION | Reduced | 21,695,003 | -2,783,265 | < 0.01% | $321,519,944 | 38 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 18,396,706 | +192,458 | < 0.01% | $272,639,183 | 3 qtrs |
| TWO SIGMA INVESTMENTS LP | Reduced | 14,964,996 | -4,045,701 | 0.16% | $221,781,241 | 10 qtrs |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Reduced | 12,279,882 | -2,109,117 | < 0.01% | $181,987,851 | 3 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 10,452,242 | +127,416 | < 0.01% | $154,930,479 | 38 qtrs |
| D E Shaw & Co Inc | Added | 9,163,428 | +7,020,294 | 0.06% | $135,802,003 | 28 qtrs |
| DIMENSIONAL FUND ADVISORS LP | Reduced | 6,238,693 | -221,756 | 0.02% | $92,443,267 | 33 qtrs |
| The Goldman Sachs Group Inc | Reduced | 4,937,725 | -158,609 | < 0.01% | $73,177,091 | 38 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- October 09, 2026
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 1,095,740
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.